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Introduction
Lung cancer is the leading cause of cancer-related deaths (1). 
Approximately 80% of lung cancer cases are non–small cell lung 
carcinoma (NSCLC). Conventional cytotoxic therapeutics show 
limited effectiveness; but recent targeted therapies utilizing 
inhibitors targeting specific driver gene activating mutations, 
such as EGFR and ALK, have demonstrated promising improved 
clinical outcomes (2–4). However, effective targeted therapies 
for other common somatic mutations such as LKB1 (STK11) in 
lung cancer remain an unmet medical need.
The LKB1 gene encodes a serine-threonine kinase that plays 
critical roles in cell growth, polarity, and metabolism (5, 6). LKB1 is 
a tumor suppressor gene whose mutations cause Peutz-Jeghers syn-
drome, which is associated with increased cancer risk (7, 8). LKB1 
is a target for mutational inactivation in sporadic cancers, espe-
cially NSCLC, where it is mutated in approximately 20%–30% 
of cases, making it the third most common site of genetic altera-
tions after TP53 and KRAS (9–12). LKB1 mutations have been 
linked with lung cancer progression and differential treatment 
responses. LKB1 loss was found to promote lung cancer metastasis 
in a KRAS mouse model of NSCLC (13). Importantly, LKB1 inacti-
vation influenced the responsiveness of cancer cells to treatments 
in vitro and in vivo. For instance, LKB1 loss sensitized NSCLC 
responses to the metabolism drug phenformin and a COX2 inhib-
itor (14, 15). On the other hand, LKB1 loss impaired the responses 
of KRAS mutant NSCLC to docetaxel monotherapy; the combi-
nation therapy of docetaxel and the MEK inhibitor selumetinib; 
or dual inhibition of the PI3K and MEK pathways (16, 17). Addi-
tionally, LKB1 mutations were associated with the modulation of 
immune microenvironments, thus potentially impacting immu-
notherapeutic outcomes (18, 19). The current data emphasize the 
need to determine tumor LKB1 status for patient stratification for 
evaluating therapeutic responses and identifying effective treat-
ments. However, detection of LKB1 functional loss is technically 
challenging because LKB1 function can be inactivated by mul-
tiple mechanisms, such as somatic gene mutations, epigenetic 
silencing, posttranslational modifications, and alterations in LKB1 
pathway components (20–22). Clinical trials for evaluating treat-
ment efficacy on LKB1-inactivated NSCLC are lacking due to the 
absence of reliable assays for accurate determination of tumor 
LKB1 status. Therefore, sensitive and specific assays for LKB1 
The LKB1 tumor suppressor gene is frequently mutated and inactivated in non–small cell lung cancer (NSCLC). Loss of LKB1 
promotes cancer progression and influences therapeutic responses in preclinical studies; however, specific targeted therapies 
for lung cancer with LKB1 inactivation are currently unavailable. Here, we have identified a long noncoding RNA (lncRNA) 
signature that is associated with the loss of LKB1 function. We discovered that LINC00473 is consistently the most highly 
induced gene in LKB1-inactivated human primary NSCLC samples and derived cell lines. Elevated LINC00473 expression 
correlated with poor prognosis, and sustained LINC00473 expression was required for the growth and survival of LKB1-
inactivated NSCLC cells. Mechanistically, LINC00473 was induced by LKB1 inactivation and subsequent cyclic AMP–responsive 
element–binding protein (CREB)/CREB-regulated transcription coactivator (CRTC) activation. We determined that LINC00473 
is a nuclear lncRNA and interacts with NONO, a component of the cAMP signaling pathway, thereby facilitating CRTC/
CREB-mediated transcription. Collectively, our study demonstrates that LINC00473 expression potentially serves as a robust 
biomarker for tumor LKB1 functional status that can be integrated into clinical trials for patient selection and treatment 
evaluation, and implicates LINC00473 as a therapeutic target for LKB1-inactivated NSCLC.
cAMP/CREB-regulated LINC00473 marks LKB1-
inactivated lung cancer and mediates tumor growth
Zirong Chen,1,2 Jian-Liang Li,3 Shuibin Lin,1,2 Chunxia Cao,2,4 Nicholas T. Gimbrone,5 Rongqiang Yang,1,2 Dongtao A. Fu,6  
Miranda B. Carper,7 Eric B. Haura,8 Matthew B. Schabath,9 Jianrong Lu,2,10 Antonio L. Amelio,7 W. Douglas Cress,5  
Frederic J. Kaye,2,4 and Lizi Wu1,2
1Department of Molecular Genetics and Microbiology and 2UF Health Cancer Center, College of Medicine, University of Florida, Gainesville, Florida, USA. 3Sanford Burnham Prebys Medical Discovery Institute 
at Lake Nona, Orlando, Florida, USA. 4Department of Medicine, College of Medicine, University of Florida, Gainesville, Florida, USA. 5Department of Molecular Oncology, Moffitt Cancer Center, Tampa, 
Florida, USA. 6Department of Pathology, Immunology and Laboratory Medicine, College of Medicine, University of Florida, Gainesville, Florida, USA. 7Lineberger Comprehensive Cancer Center, University 
of North Carolina at Chapel Hill, Chapel Hill, North Carolina, USA. 8Department of Thoracic Oncology and 9Department of Cancer Epidemiology, Moffitt Cancer Center, Tampa, Florida, USA. 10Department of 
Biochemistry and Molecular Biology, College of Medicine, University of Florida, Gainesville, Florida, USA.
Note regarding evaluation of this manuscript: Manuscripts authored by scientists 
associated with Duke University, The University of North Carolina at Chapel Hill, 
Duke-NUS, and the Sanford-Burnham Medical Research Institute are handled not by 
members of the editorial board but rather by the science editors, who consult with 
selected external editors and reviewers.
Conflict of interest: The authors have declared that no conflict of interest exists.
Submitted: October 27, 2015; Accepted: March 10, 2016.
Reference information: J Clin Invest. 2016;126(6):2267–2279. doi:10.1172/JCI85250.
The Journal of Clinical Investigation R e s e a R c h  a R t i c l e
2 2 6 8 jci.org   Volume 126   Number 6   June 2016
and Supplemental Table 1). We also observed 17 upregulated and 
49 downregulated lncRNAs associated with LKB1-K78I mutant 
expression compared with control (Figure 1C and Supplemen-
tal Table 2). Comparing expression profiles of LKB1-WT– and 
LKB1-K78I–expressing cells, we identified 33 upregulated and 83 
downregulated lncRNAs, which suggests that their expression is 
dependent on LKB1 kinase activity (Supplemental Table 3). Fur-
thermore, we profiled and compared lncRNA expression patterns 
in two groups of cell lines — LKB1-null (A549, H460) and LKB1-
WT (H322, H3123) — and observed 1,449 upregulated and 918 
downregulated lncRNAs in LKB1-null cell lines (Figure 1D and 
Supplemental Table 4). Finally, by integrating LKB1-regulated 
lncRNAs and lncRNAs differentially expressed in LKB1-null cell 
lines (Supplemental Table 1 and Supplemental Table 4), we identi-
fied a list of LKB1-regulated lncRNAs (10 upregulated and 1 down-
regulated) that were differentially expressed between LKB1-null 
and -WT lung cancer cells (Supplemental Table 5).
Notably, this list contained 3 transcripts for the LINC00473 
gene (also known as C6orf176), which encodes an intergenic 
lncRNA from the chromosome 6q27 locus. LINC00473 consists 
of two exons and has two annotated RefSeq transcript isoforms 
sharing exon 1: transcript variant 1 (tv1; NR_026860, 1822 nt) 
and tv2 (NR_026861, 1123 nt) (Supplemental Figure 2A). Our 5′ 
and 3′ rapid amplification of cDNA ends (RACE) assays identi-
fied 3 LINC00473 transcript variants, tv1.1, tv2.1, and tv2.2, but 
not the two annotated transcripts (Supplemental Figure 2, B and 
C). LINC00473 tv1.1 had a shorter 5′ end than the annotated 
tv1, while tv2.1 and tv2.2 each had 5′ and 3′ ends that were differ-
ent from the annotated tv2. Coding potential analysis strongly 
suggested that LINC00473 is a noncoding RNA (Supplemental 
Figure 2, D and E). Both tv1 and tv2 transcript variants showed 
significant activation in LKB1-null NSCLC cells (Supplemental 
Table 5). LINC00473 tv1 was the top differentially expressed 
lncRNA (>10,000-fold change) when the two LKB1-null (A549 
and H460) lines were compared with the two LKB1-expressing 
cells (H322 and H3123), while LINC00473 tv2 showed about a 
40-fold change.
Elevated LINC00473 expression is tightly correlated with 
NSCLC LKB1 inactivation status. To validate LKB1-regulated 
lncRNAs, we utilized a NanoString-based assay that allows direct 
digital detection of multiple RNA molecules of interest using tar-
get-specific, color-coded probe pairs (34). This platform enabled 
us to simultaneously evaluate multiple LKB1-regulated mRNA 
and lncRNA candidates (especially LINC00473). Hybridizations 
were performed on RNA samples from a pair of control and LKB1-
expressing A549 cells and a panel of NSCLC cell lines (7 LKB1-WT 
and 7 LKB1-mutant) using a customized codeset. The codeset 
included several LKB1-regulated lncRNA candidates, known 
LKB1-regulated protein-coding genes (35, 36), as well as three 
housekeeping genes (GAPDH, GUSB, and TUBB). As shown in the 
heatmap (Figure 1E, right), LKB1 expression in LKB1-null A549 
cells caused significant downregulation of known protein-coding 
genes (AVPI1, CTH, CPS1, DUSP4, FGA, NR4A2, PDE4B, PDE4D, 
PTGS2, PTP4A1, SIK1, SLC7A2, SNAI1, TESC, and TFF1), as well 
as three lncRNAs (LINC00473, AL109792, and BX641110). 
However, when examined across various cell lines with the con-
firmed status of cellular LKB1 protein expression (Supplemental 
inactivation as well as effective targeted therapeutics are needed 
for effective management of LKB1-inactivated NSCLC.
Long noncoding RNAs (lncRNAs) are non-protein-coding 
transcripts longer than 200 nucleotides and represent a novel 
class of gene regulators (23). The human genome encodes more 
than 10,000 lncRNAs,  and currently only a handful of lncRNAs 
have been characterized (24–26). lncRNA expression is fre-
quently deregulated in cancer and shows cell- or tissue-type 
specificity (27–29), suggesting significant roles for lncRNAs in 
human cancers. Though lncRNAs remain an understudied class 
of genes, they have been shown to participate in cancer cell prolif-
eration, survival, migration, and invasion, likely through exertion 
of multiple regulatory functions at the transcriptional, posttran-
scriptional, and epigenetic levels (23, 30). Importantly, target-
ing cancer-associated lncRNAs, such as HOTAIR and MALAT1, 
blocked cancer cell growth and survival in vitro and tumor growth 
and metastasis in vivo (31, 32). Therefore, lncRNAs are criti-
cal for cancer development and progression and might serve as 
novel therapeutic targets. Currently, the molecular mechanisms 
underlying LKB1 tumor suppression remain incompletely under-
stood (5, 33). Whether lncRNAs have a role in mediating the loss 
of LKB1 tumor suppression in lung cancer has not been studied.
In this study, we performed lncRNA transcriptional pro-
filing to identify lncRNAs that are associated with inactivated 
LKB1 signaling. We subsequently focused on one novel LKB1- 
regulated lncRNA (LINC00473) because it was consistently 
the most highly induced target identified with LKB1 loss. The 
elevated expression of LINC00473 was associated with poor 
patient prognosis and tightly correlated with LKB1 inactivation 
status in human lung cancer specimens and derived cell lines. 
Our expression, functional, and mechanistic data demonstrate 
that LINC00473 is a potentially robust biomarker for detection 
of lung cancers with inactivated LKB1, a novel therapeutic target, 
and a novel gene regulator.
Results
Genome-wide lncRNA profiling identified LINC00473 as a top LKB1 
signaling–regulated lncRNA in NSCLC cells. The involvement of 
lncRNAs in altered LKB1 signaling in lung cancer has not to our 
knowledge been studied. To investigate whether lncRNAs con-
tribute to loss of LKB1 tumor suppression in lung tumorigenesis 
and maintenance, we performed genome-wide lncRNA transcrip-
tional profiling to identify lncRNAs associated with aberrant LKB1 
signaling. We generated three groups of cells by transducing LKB1-
null A549 NSCLC cells with retroviruses harboring WT LKB1, an 
LKB1 kinase-dead mutant (K78I), or a vector control. Western blot 
analysis confirmed expression and kinase activity of LKB1-WT 
and -K78I proteins in an AMPK activation assay under glucose-
free culture conditions (Figure 1A and Supplemental Figure 1; sup-
plemental material available online with this article; doi:10.1172/
JCI85250DS1). We subsequently used Arraystar Human LncRNA 
Expression Microarrays to profile changes in expression of approx-
imately 30,000 lncRNAs in our three experimental conditions. 
Using an absolute fold change of at least 2.0 and a P value less 
than 0.05, we identified a total of 164 differentially expressed 
lncRNAs (64 upregulated and 100 downregulated) in A549 cells 
upon LKB1-WT expression compared with control (Figure 1B 
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cell lines using Affymetrix microarray data from the Cancer Cell 
Line Encyclopedia (CCLE) (37), and these arrays only contained 
the probes for LINC00473 tv1. We found that a subset of NSCLC 
cell lines showed outlier LINC00473 tv1 expression levels (Figure 
1H and Supplemental Table 6). Analysis of cell lines with anno-
tated LKB1 mutation status revealed that LINC00473 expression 
was significantly enhanced in LKB1-mutant NSCLC cell lines 
(n = 32) in comparison to LKB1-WT lines (n = 59) (Supplemental 
Table 6 and Figure 1I), and the enhancement was more signifi-
cant as compared with the increase in SIK1 expression (Supple-
mental Figure 3D). Furthermore, two LKB1-WT cell lines with 
high LINC00473 expression, H292 and DV90, were predicted to 
have LKB1 loss based on a 16-gene signature score (35). H292 is a 
lung mucoepidermoid carcinoma cell line that contains a t(11;19) 
translocation that leads to the generation of CREB-regulated 
Figure 3A), LINC00473 expression showed the best correla-
tion with LKB1-inactivated status (Figure 1E, left and middle). 
Other LKB1-regulated genes, including lncRNAs AL109792 and 
BX641110, were only partially correlated with the LKB1 status, 
suggesting cell context–dependent gene regulation.
Both the LINC00473 tv1 and tv2 isoforms showed low or 
absent expression in 7 LKB1-WT NSCLC cell lines but signifi-
cantly enhanced expression in 7 LKB1-mutant cell lines (Figure 
1, F and G). LINC00473 differential expression in LKB1-WT and 
LKB1-mutant cell lines was further corroborated by quantitative 
RT-PCR (qRT-PCR) data (Supplemental Figure 3B). Enhanced 
expression of a known LKB1 target gene, SIK1, was also confirmed 
but was not consistent across all cell lines tested (Supplemental 
Figure 3C). Moreover, SIK1 has relatively high basal expression. 
Additionally, we surveyed LINC00473 expression in 130 NSCLC 
Figure 1. lncRNA profiling revealed that LINC00473 is induced by LKB1 loss in NSCLC cells. (A) Western blot analysis of expression of LKB1-WT or kinase-
dead K78I mutant in transduced LKB1-null lung adenocarcinoma A549 cells. A549 cells infected with pBabe vector retroviruses were used as controls (Ctl). 
(B and C) Volcano plots show differentially expressed lncRNAs after expression of LKB1-WT (B) or LKB1-K78I mutant (C) in A549 cells by lncRNA microarray 
(V3.0) analysis. The cutoff criteria was an absolute fold-change of ≥2 and P < 0.05.  (D) A volcano plot shows differentially expressed lncRNAs in two LKB1-null 
cell lines (A549 and H460) as compared with two LKB1-WT cell lines (H322 and H3123). (E) A heatmap shows expression levels of several LKB1-regulated pro-
tein-coding and noncoding genes measured in NanoString assays. (F and G) Two LINC00473 (Lnc473) transcript variants (tv1: NR_026860 and tv2: NR_026861) 
show significantly elevated expression in LKB1-mutant (Mut) groups as compared with LKB1-WT groups based on the NanoString assays. (H) CCLE data anal-
ysis identified NSCLC cell lines (n = 130) with outlier LINC00473 expression levels. (I) Enhanced LINC00473 expression was significantly associated with LKB1 
mutations in CCLE NSCLC cell lines. See also Supplemental Figures 1–3 and Supplemental Tables 1–6.
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Figure 2. Enhanced LINC00473 expression is highly correlated with human lung adenocarcinoma with LKB1 mutational status and is associated with poor 
survival. (A) A heatmap shows gene expression levels in RNA samples isolated from 5 LKB1-WT and 5 LKB1-mutant FFPE LUAD samples in NanoString assays. 
(B) Expression of LINC00473 tv1, but not tv2, was significantly different between LKB1-WT and -mutant groups. (C and D) Representative images for tumors with 
LINC00473-positive (C) and -negative (D) signals based on RNAscope detection on FFPE LUAD sections. RNA ISH of the housekeeping gene PPIB was performed 
for sample RNA quality control. Scale bars: 100 μm (left panels), 25 μm (right panels). (E) A survey of human LUAD arrays indicated that 0% of normal lung tissues 
(n = 38), 10.11% of NSCLC tumors with annotated WT LKB1 (n = 89), and 55.54% of NSCLC tumors with annotated LKB1 mutations (n = 22) were positive for 
LINC00473 expression. Only those tissues positive for the housekeeping gene PPIB expression were included in this analysis. LINC00473 expression was positively 
correlated with LKB1 mutations based on Fisher’s exact test (P = 1.93 × 10–5). (F) TCGA-LUAD dataset showed outlier LINC00473 expression in matched tumor (T) 
(n = 57) compared with adjacent normal tissues (N) (n = 57) as well as unpaired tumor (UT) (n = 454). (G) Kaplan-Meier survival analysis of high LINC00473 expres-
sion (n = 48) and low LINC00473 expression (n = 421) in lung cancer patients (P < 0.001). See also Supplemental Figures 4–8 and Supplemental Table 7.
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small target regions (~100 bp), allowing direct single-molecule 
counting without the need for target amplification (34). Therefore, 
we performed NanoString assays for FFPE tumor-derived RNAs 
from 5 LKB1-WT and 5 LKB1-mutant human LUAD specimens. 
The LKB1 gene mutation status was analyzed by exon sequencing 
as previously described (19), and the results are shown in Supple-
mental Table 7. LINC00473 expression was consistently found to 
best correlate with tumor LKB1 status among all the genes tested 
(Figure 2A). Expression of LINC00473 tv1, but not tv2, was sig-
nificantly enhanced in LUAD with LKB1 mutations (Figure 2B). 
These data suggest that expression of LINC00473 tv1 alone can 
predict tumor LKB1 status.
To examine whether LINC00473 expression could be directly 
visualized at the cellular level in human FFPE tumors, we next 
performed RNA in situ hybridizations (RNA ISH) for detec-
tion of LINC00473 transcripts using customized LINC00473 
probes (RNAscope). The specificity of LINC00473 probes was 
first validated by positive LINC00473 signals in LKB1-null 
A549 xenograft tumors and negative signals in LKB1-WT H522 
xenograft tumors (Supplemental Figure 4, A and B). LINC00473 
transcription coactivator–MAML2 (CRTC1-MAML2) fusion (38) 
and subsequent constitutive activation of cyclic AMP–responsive 
element–binding protein–mediated (CREB-mediated) transcrip-
tion, thus mimicking LKB1 loss. Collectively, these data strongly 
support that LINC00473 is consistently the most elevated gene in 
LKB1-inactivated NSCLC cell lines regardless of other coexisting 
gene mutations.
Direct RNA detection in FFPE specimens revealed that 
LINC00473 expression is elevated in a subset of NSCLCs that tend 
to have mutations in the LKB1 gene coding regions. To investigate 
whether LINC00473 could serve as a potential biomarker for 
LKB1 status in human NSCLC cancers, we evaluated expression 
of LINC00473 and several other LKB1 targets in formalin-fixed, 
paraffin-embedded (FFPE) human lung adenocarcinoma (LUAD) 
specimens. Target amplification–based strategies such as RT-PCR 
and microarray analyses for measuring RNA levels from fixed tis-
sue is complicated by the fact that the RNA is highly cross-linked 
and significantly fragmented. NanoString-based assays are opti-
mal for gene expression quantification using FFPE tumor-derived 
RNA samples, since the barcoded fluorescent probes recognize 
Figure 3. LINC00473 expression is regulated by the LKB1/CRTC1/CREB signaling axis. (A) qRT-PCR analysis showed that LINC00473 expression was signifi-
cantly reduced in two LKB1-null NSCLC cell lines (H157 and A549) after transduction with LKB1 retroviruses (LKB1) for 96 hours, with cells transduced with 
vector retroviruses (Ctl) used as controls. Western blotting confirmed LKB1 expression (n = 3, **P < 0.001). (B) LINC00473 expression was enhanced upon 
LKB1 shRNA lentiviral infection in two LKB1-WT NSCLC cell lines (H3123 and H322) (n = 3, *P < 0.05 and ***P < 0.0001). (C) LINC00473 expression was sig-
nificantly reduced in A549 cells after  transduction with two independent CREB shRNAs (n = 3, *P < 0.05). (D) A schematic representation of the LINC00473 
promoter reporter. (E) Expression of LKB1, but not the kinase-dead K78I mutant in LKB1-null A549 cells caused significant repression of LINC00473 promoter 
reporter activity (n = 3, *P < 0.05). (F) Expression of A-CREB in A549 cells significantly inhibited the LINC00473 promoter (Pro) activity (n = 3, *P < 0.05). (G) 
Expression of WT or constitutively activated S151A CRTC1 increased LINC00473 promoter activity in LKB1-expressing H322 cells (n = 3, **P < 0.001 and  
***P < 0.0001). (H) ChIP analysis indicated that CREB and CRTC1 were significantly enriched on the LINC00473 promoter encompassing the CRE half sites  
in A549 cells (n = 3, *P < 0.05 and ***P < 0.0001). See also Supplemental Figure 9.
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transcripts were detected as easily distinguishable nuclear “dots” 
in A549 xenograft tumors (Supplemental Figure 4, A and C). We 
then performed RNA ISH on an FFPE human LUAD tissue array. 
This array also included FFPE cell pellets from LKB1-null A549 
and LKB1-positive H322 as controls, which showed positive and 
negative LINC00473 signals, respectively (Supplemental Figure 
4, D and E). We analyzed only those tumors that were positive for 
the housekeeping gene peptidylprolyl isomerase (PPIB), indic-
ative of tumors with good RNA quality. Representative positive 
and negative LINC00473 staining results are shown (Figure 2, 
C and D). We found that all normal human lung tissues (n = 38) 
were negative for LINC00473 staining while exhibiting positive 
staining for PPIB staining (Figure 2E and Supplemental Figure 
4F), indicating absent or low basal LINC00473 expression in nor-
mal lung tissues. A total of 9 of 89 NSCLC specimens (10.11%) 
with annotated LKB1-WT and 12 of 22 lung tumors (54.54%) with 
annotated LKB1 mutations were positive for LINC00473 staining 
(Figure 2E and Supplemental Figure 4, G–J). LINC00473 expres-
sion showed significant positive correlation with LKB1 muta-
tions based on Fisher’s exact test (P = 1.93 × 10–5). It is likely that 
those tumors carrying the LKB1-WT gene yet showing elevated 
LINC00473 expression have LKB1 functional inactivation due 
to other mechanisms besides LKB1 mutations, such as epigenetic 
silencing, posttranslational modifications, or alteration in LKB1 
signaling components (20–22). On the other hand, it is worth not-
ing that not all mutations found in LKB1 are inactivating. Tumors 
carrying the LKB1 gene mutations yet not showing LINC00473 
induction could have intact LKB1 function if the mutations do 
not impair LKB1 function. For example, one of the tumors with 
LKB1 F354L mutation, which was predicted not to have damag-
ing effects on LKB1 function based on PolyPhen-2 prediction (39), 
showed undetectable LINC00473 expression. In addition, nega-
tive LINC00473 staining was found in several other cancer types 
and tissues, including prostate cancer, invasive ductal carcinoma 
(IDC) breast, large cell lymphoma, hepatocellular carcinoma, 
colon adenocarcinoma, and osteosarcoma, as well as placenta, 
tonsil, and normal spleen (n = 1; data not shown). These data 
strongly indicate that LINC00473 is low or undetectable in nor-
mal lung tissues but exhibits elevated expression in the subset of 
lung NSCLC specifically with functional LKB1 inactivation, indi-
cating that LINC00473 is a potential robust surrogate biomarker 
for LKB1 functional status in lung cancer.
Elevated LINC00473 expression is associated with tumor 
LKB1 mutations and correlated with poor prognosis in TCGA lung 
adenocarcinomas. To investigate any potential association among 
LINC00473 expression, LKB1 mutation status, and clinical lung 
Figure 4. Depletion of LINC00473 expression in LKB1-null NSCLC cells causes reduced cell growth and survival in vitro and in vivo. (A) Luciferase-
expressing A549 cells were infected with one of two lentiviral-based LINC00473 shRNAs or the scrambled shRNA control (shCtl). Transduced cells were 
harvested 96 hours later, and LINC00473 expression was quantified by qRT-PCR (n = 3, *P < 0.05). (B and C) Transduced cells at 96 hours after transduction 
were cultured at 2 × 105 per well in 6-well plates for another 96 hours, and viable cell numbers were measured using a trypan blue assay (B), and apoptotic 
cells were detected by Annexin V/PI staining (C) (n = 3, **P < 0.001). (D–F) A total of 1 × 106 A549-luc cells after transduction with shLINC00473 or shCtl 
for 72 hours were injected subcutaneously into the dorsal flanks of NOD/SCID mice. Representative bioluminescent images of mice injected with shCtl or 
shLINC00473 A549-luc cells (D) and the weights of excised tumors (E) at the end points are shown. Tumor growth is shown at different days after tumor 
cell injection (F). (*P < 0.05, **P < 0.001, ***P < 0.0001). (G) Immunohistochemical staining of A549-control and A549-shLINC00473 xenograft tumor 
sections with Ki-67 antibody. See also Supplemental Figures 10–11. Scale bars: 50 μm (left panels), 25 μm (right panels).
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cancer data, we examined a LUAD RNAseq dataset from The Can-
cer Genome Atlas (TCGA) (40). We observed a subset of lung can-
cers with outlier LINC00473 expression (90th percentile rank) 
and a significant difference in LINC00473 expression between 
tumors (either paired, n = 57; or unpaired, n = 454) and normal 
tissues (n = 57) (Figure 2F). LUAD samples with high LINC00473 
expression were enriched with LKB1 gene–level nonsynony-
mous somatic mutations, including small insertions or deletions 
(INDELs) within the LKB1 gene coding regions (Supplemental 
Figure 5). LINC00473 expression was not associated with KRAS 
and TP53 gene mutations (Supplemental Figure 5), which are two 
well-known somatic mutations that can occur concurrently with 
LKB1 loss. Moreover, the difference in LINC00473 expression 
between LKB1-WT and LKB1-mutant populations was more sig-
nificant compared with SIK1 or LKB1 expression (Supplemental 
Figure 6). LINC00473 expression was positively correlated with 
LKB1-loss gene signature (35) and inversely correlated with LKB1 
expression, and such correlations were more significant in com-
parison to SIK1 expression and LKB1 expression (Supplemental 
Figure 7). These data support a strong association of LINC00473 
expression with the LKB1 inactivation in LUAD samples.
Kaplan-Meier survival analysis showed highly significant dif-
ference in overall survival between the high expression (n = 48) and 
low expression (n = 421) groups (P < 0.001, Figure 2G). The elevated 
LINC00473 expression significantly correlated with a shorter sur-
vival time in LUAD patients (<50 months). When analyzing those 
tumors with the available data on LINC00473 expression, LKB1 
mutations, and the clinical information, we observed that LKB1 
mutation status was not significantly associated with survival, but 
high LINC00473 expression was associated with poor survival 
within both the LKB1-WT and -mutant groups (Supplemental Figure 
8). These data indicate that LINC00473 has a prognostic value and 
may play an important role in cancer progression.
LINC00473 expression is promoted by LKB1 loss–induced CRTC/
CREB activation. High LINC00473 expression has a positive cor-
relation with LKB1 functional inactivation in NSCLC cell lines and 
human primary tumors, suggesting that LKB1 inactivation leads to 
increased expression of LINC00473. To further examine LKB1 reg-
ulation of LINC00473 expression, we first tested whether cellular 
LKB1 levels directly impacted LINC00473 expression. We observed 
that introduction of exogenous LKB1 in LKB1-null cancer cell lines 
(H157, A549) resulted in a significant decrease in LINC00473 tran-
script level (Figure 3A), whereas shRNA-mediated depletion of 
endogenous LKB1 expression in LKB1-positive cells (H3123, H322) 
led to an increase in LINC00473 levels (Figure 3B). Therefore, 
modulating cellular LKB1 protein expression affects LINC00473 
expression in NSCLC cells.
LKB1 regulates multiple downstream AMPK family mem-
bers, influencing multiple signaling pathways (5). We previously 
showed that loss of LKB1 expression resulted in dephosphory-
lation and nuclear entry of CRTC transcriptional coactivators 
and subsequent CREB-mediated transcriptional activation in 
both lung and esophageal cancer cells (41, 42). LINC00473 was 
transiently upregulated in response to cAMP signaling in human 
ocular ciliary smooth muscle cells (43). The LINC00473 gene 
contains two cAMP-responsive element (CRE) half sites within 
the proximal promoter region. To test whether the loss of LKB1 
induces CRTC/CREB activation and promotes LINC00473 
expression, we first depleted CREB using lentiviral-mediated 
shRNAs or expressed a dominant negative form of CRTC 
(dnCRTC) that interferes with CRTC/CREB interaction. We 
detected a reduction in the LINC00473 transcript level in 
CREB-depleted or dnCRTC-expressing A549 cells (Figure 
3C and Supplemental Figure 9). LKB1 overexpression fur-
ther blocked LINC00473 expression (Supplemental Figure 9). 
These data demonstrate that LINC00473 is regulated by LKB1 
loss and CRTC/CREB activation. Next, we cloned the proximal 
LINC00473 promoter sequence (–523 to +88) encompassing 
two CRE sites into the upstream region of a luciferase reporter 
(pGL3 basic) (Figure 3D) and then determined LINC00473 pro-
moter activity by modulating LKB1/CRTC/CREB signaling. We 
observed that the LINC00473 promoter reporter was significantly 
repressed by overexpression of LKB1, but not the LKB1 kinase-
dead mutant K78I, when transfected in LKB1-deficient A549 cells 
(Figure 3E). Moreover, promoter activity was significantly inhib-
ited by expression of A-CREB (Figure 3F), a dominant-negative 
mutant that specifically blocked CREB binding to DNA (44, 45). 
Also, the LINC00473 promoter reporter was activated by over-
expression of CRTC1 and, to a greater extent, by a constitutively 
activated form of CRTC1 (S151A) (Figure 3G). Finally, chromatin 
immunoprecipitation (ChIP) assays demonstrated that CRTC1 
and CREB were enriched in the LINC00473 promoter region 
spanning the CRE sites (Figure 3H). Overall, these data suggest 
that LINC00473 transcription is directly induced by CRTC/
CREB activation in LKB1-inactivated NSCLC cells.
In vitro and in vivo approaches revealed critical functions of 
LINC00473 in the growth of LKB1-null lung cancer cells. High 
LINC00473 expression correlated with poor survival of lung 
cancer patients (Figure 2G), indicating a role for LINC00473 in 
cancer progression. Therefore, we investigated the functional 
significance of sustained LINC00473 expression in LKB1- 
inactivated NSCLC cells. We first determined the functional 
impact of LINC00473 depletion on cell growth and survival using 
two independent lentiviral pLKO.1-based shRNAs targeting exon 2 
of LINC00473 tv1 (shLnc473-2 and shLnc473-4). We found that two 
shLnc473 caused an approximately 90% reduction in LINC00473 
transcript levels in A549 cells at 96 hours after lentiviral infec-
tion (Figure 4A). The shLnc473-expressing as well as scrambled 
shRNA control–expressing cells were subsequently assayed for 
cell growth and survival. LINC00473 knockdown reduced cell 
proliferation and enhanced apoptosis in LKB1-null A549 cells 
(Figure 4, B and C). Similar effects of LINC00473 depletion on the 
LKB1-null NSCLC cell line H157 were also observed (Supplemen-
tal Figure 10). Conversely, exogenous LINC00473 overexpression 
via retroviral transduction in LKB1-WT H522 lung cancer cells 
resulted in a moderate,  yet significant increase in cell proliferation 
(Supplemental Figure 11, A and B). These data demonstrate that 
LINC00473 is essential for maintaining LKB1-inactivated lung 
cancer cell growth and survival.
We next determined the effect of LINC00473 depletion on 
the growth of NSCLC xenografts. The luciferase-expressing 
A549 (A549-luc) cells were transduced with lentiviral-based 
shLnc473 or scrambled shRNA control for 72 hours, and then 
equal numbers of LINC00473-depleted and control cells were 
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ure 6B). We also performed RNA immunoprecipitation (RNA-IP) 
for the RNA-NONO complex using NONO antibodies and mea-
sured the amount of LINC00473 associated with NONO immuno-
precipitates. The immunoprecipitated NONO protein levels were 
confirmed by Western blotting (Figure 6C). The qRT-PCR results 
showed significant enrichment of LINC00473, but not the negative 
control, ASNS, in NONO immunoprecipitates (Figure 6D). These 
data indicate that NONO is an LINC00473-associated protein.
NONO interacts with CRTC coactivators upon cAMP stimu-
lation, which is essential for CREB-mediated transcription (47). 
Since LINC00473 physically interacted with NONO, we hypoth-
esize that LINC00473 regulates NONO recruitment to CRTCs 
and promotes subsequent activation of CREB target gene tran-
scription. To test this hypothesis, we determined the interaction 
of NONO and CRTC when LINC00473 was either depleted 
or overexpressed using mammalian two-hybrid assays. We 
observed that depletion of LINC00473 caused a reduced interac-
tion of Gal4-NONO and CRTC1, which was indicated by reduced 
activation of a Gal4 promoter reporter (Figure 6E). Conversely, 
enhanced LINC00473 expression promoted NONO-CRTC1 
interaction (Figure 6F). These data suggest that LINC00473 
facilitates the recruitment of NONO to CRTC and subsequently 
promotes CREB-mediated transcription. To further examine 
whether LINC00473 regulates endogenous CRTC/CREB target 
genes, we performed gene expression analysis in lentiviral-based 
scrambled shRNA control and LINC00473-depleted A549 cells, 
as well as in retroviral-based vector control and LKB1-expressing 
A549 cells in NanoString assays. LINC00473 depletion impaired 
expression of several known and potential CRTC/CREB targets, 
including CTH, CPS1, DUSP4, FGA, NR4A2, PDE4B, PDE4D, 
PTGS2, PTP4A1, SIK1, SLC7A2, TESC, and TFF1, expression of 
which was induced by LKB1 loss (Figure 6G). Moreover, NEDD9, 
a CRTC/CREB target gene implicated in regulating cell prolifer-
ation and metastasis (48), was downregulated in LINC00473- 
depleted A549 cells, although its expression was not significantly 
different between LKB1-mutant and -WT cell lines (Supple-
mental Figure 13). Furthermore, qRT-PCR analysis showed that 
expression of exogenous LINC00473 in LKB1-WT H522 signifi-
cantly promoted transcription of several CREB target genes, such 
as CPS1, PDE4B, PTGS2, and PDE4D (Supplemental Figure 11C). 
All these data support a model whereby LINC00473 acts as a 
coactivator with CRTC/CREB in a positive feedback mechanism 
to maintain high steady-state levels and induce expression of 
other LKB1-regulated targets (Figure 7).
Discussion
Lung cancer is the leading cause of cancer death. Progress 
in lung cancer treatment will require improved predictive 
biomarkers so that cancer patients can be provided with the 
most effective treatments available, as well as a larger repertoire 
of therapeutic targets. In this study, we discovered an lncRNA 
(LINC00473) whose elevated expression was highly associated 
with loss function of the tumor suppressor LKB1 gene, one of 
the most common mutational events in lung cancer. Our gene 
expression and functional data strongly support the potential 
utility of LINC00473 as a biomarker and as a therapeutic tar-
get for lung cancers with impaired LKB1 signaling. Moreover, 
implanted into NOD/SCID mice by subcutaneous injection. 
We observed that LINC00473 depletion significantly reduced 
tumor size and weight, and blocked the growth of A549-luc 
xenografts over time (Figure 4, D–F). IHC analysis showed that 
LINC00473-depleted xenograft tumors contained a reduced 
number of cells that were positive for the cell proliferation 
marker Ki-67 (Figure 4G). Similarly, depletion of LINC00473 
expression decreased the growth of H157 xenografts in NOD/
SCID mice (Supplemental Figure 10, D–F). Therefore, both 
in vitro and in vivo evidence supports the critical functions of 
LINC00473 in regulating lung cancer growth and survival.
LINC00473 is a nuclear lncRNA and functions as a regulator of 
gene expression in part through interacting with NONO and modulat-
ing CRTC/CREB transcription. The molecular mechanisms under-
lying LINC00473 functions are unknown. Studies have indicated 
that lncRNAs may be involved in various processes, including tran-
scription, splicing, posttranscriptional regulation, organization of 
protein complexes, cell-cell signaling, and allosteric regulation of 
proteins (46). Knowledge of subcellular localization of lncRNAs 
can provide a clue about lncRNA functions. We observed nuclear 
localization of LINC00473 transcripts in FFPE human lung can-
cer specimens using customized LINC00473 probes in RNAscope 
RNA ISH assays (Figure 2C). To validate LINC00473 as a nuclear 
lncRNA, we performed a subcellular fractionation assay and 
RNA fluorescence in situ hybridization (RNA-FISH). For the frac-
tionation assay, we prepared cytoplasmic and nuclear fractions 
and determined LINC00473 transcript levels in both fractions. 
We confirmed that in comparison to the respective cytoplasmic 
(tRNA) and nuclear (U6) controls, LINC00473 is enriched in the 
nuclear fraction (Figure 5, A and B). For RNA-FISH, we hybridized 
fixed cells with a mixture of 27 oligonucleotide probes (20-mer) 
targeting LINC00473, with each probe linked with a single Qua-
sar 570 fluorophore. We observed positive nuclear signals with 1 
to 2 distinctive dot-like structures, as well as less intense, diffuse 
signals outside the dots (Figure 5C). LINC00473 signals were 
undetectable when hybridizations were performed in the presence 
of RNase (Supplemental Figure 12A), indicating that the signal 
detection was RNA dependent. Moreover, exogenous LINC00473 
showed similar nuclear localization when overexpressed in LKB1-
WT H522 cells (Supplemental Figure 12, B and C). These data 
strongly support that LINC00473 has distinct nuclear localization 
and likely participates in nuclear functions.
To investigate LINC00473-interacting proteins, we performed 
an RNA pull-down assay followed by a proteomic analysis of the 
LINC00473-associated protein complex in A549 cells. We incu-
bated the in vitro transcribed LINC00473 bound to beads with 
A549 nuclear extracts to purify the LINC00473 RNA-protein 
complex. The LINC00473-associated protein complex compo-
nents were separated by SDS-PAGE (Figure 6A), and the protein 
identity was revealed by mass spectrometry (MS). A notable pro-
tein was a known CRTC-interacting protein, NONO (47), with 115 
peptides detected in this MS analysis (Supplemental Table 8). To 
validate the physical interaction between LINC00473 and NONO, 
we performed RNA pull-down followed by Western blotting with 
NONO antibodies. NONO was readily detected in the LINC00473 
RNA pull-down complex but not in the control samples, including 
LINC00473 antisense RNA, lncRNA MEG3, and beads only (Fig-
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In this study, we observed that LINC00473 is consistently 
the most highly induced gene in LKB1-inactivated primary 
NSCLC samples and derived cell lines, supporting the notion 
that LINC00473 expression could be used for predicting 
LKB1 functional status in clinically relevant FFPE tumor spec-
imens. There are advantages in using LINC00473 as a sur-
rogate marker for tumor LKB1 functional inactivation. First, 
LINC00473 expression is a functional readout for LKB1 inacti-
vation; thus, LINC00473-based detection will be advantageous 
relative to direct sequencing of the entire LKB1 gene or IHC 
analysis for the detection of LKB1 protein. We observed that a 
subset of human lung tumors without detectable mutations in 
the coding region of the LKB1 gene showed positive staining for 
LINC00473. These tumors likely reflect scenarios where func-
tional LKB1 inactivation is caused by epigenetic effects such as 
promoter hypermethylation or functional suppression by other 
mechanisms, including alterations in other components of the 
LKB1 pathway. For example, BRAF activating mutations were 
shown to suppress LKB1 kinase activity and thus inactivated 
LKB1 signaling (20). On the other hand, a subset of tumors 
with LKB1 mutations had non-detectable LINC00473 expres-
sion. One possibility is that these tumors have LKB1 mutations 
yet such mutations have no significant impact on LKB1 func-
tions. Also, tumor cells having the mutation(s) on one allele 
of the LKB1 gene may express sufficient levels of functional 
LKB1 proteins. Second, the presence of a significant number of 
LKB1-WT stromal cells within tumors can obscure detection of 
LKB1-null tumor cells in LKB1 IHC studies. Since LINC00473 
is expressed at low or undetectable levels under normal con-
ditions but at high levels in LKB-inactivated cells, detection of 
upregulated LINC00473 expression will not be affected by the 
presence of stromal cells. Third, LINC00473 has sufficiently high 
expression in LKB1-inactivated lung cancer and can be detected 
in biopsy specimens in the clinic. We present proof-of-concept 
data showing that both NanoString-based expression assay and 
RNAscope-based RNA ISH can be used for LINC00473 detection 
in clinically relevant FFPE tumors. The NanoString-based assay is 
rapid and reproducible in clinical laboratories, and provides quan-
titative expression scores. The RNAscope-based assays, while 
requiring subjective scoring due to variable levels of staining sig-
nals, can allow colorimetric detection of LINC00473-expressing 
tumor cells to infer LKB1 functional status. Such transcript-based 
tests, capable of detecting pathway activity, are of special impor-
tance for tumor suppressor gene detection, as histologically clin-
ical diagnosis based on LKB1 IHC and DNA mutation assays are 
more difficult as compared with activated oncogene detection. 
Our data suggest the potential to develop a LINC00473 expres-
sion–based test for scoring tumors with LKB1 functional loss that 
could be integrated with clinical trial design for patient selection 
and treatment decisions. In the future, it will be important to 
identify the specific mechanisms underlying LKB1 silencing in the 
subset of “LKB1-WT, LINC00473-positive” tumors or intact func-
tional LKB1 signaling in “LKB1-mutant, LINC00473-negative” 
tumors. Due to the complexity of working with stored primary 
tumors with heterogeneous stromal contamination, this effort 
will require extensive follow-up studies using fresh samples at the 
genomic, epigenomic, and expressional levels.
we provide mechanistic insights into LINC00473 as a critical 
nuclear regulator of gene expression in lung cancer.
Recent studies reveal that specific lncRNA expression is 
associated with disease state (27, 49), strongly supporting the 
utility of lncRNAs in clinical diagnosis and prognosis. Loss of 
LKB1 function in NSCLC cells caused differential responses to 
therapeutic agents in vitro and in animal studies. LKB1 inactiva-
tion sensitized NSCLC cells to the metabolism drug phenformin 
and a COX2 inhibitor while conferring resistance to PI3K/Akt 
and MEK inhibitors (14–17). However, no specific effective treat-
ments are currently available for patients with LKB1-deficient 
lung cancer. One big barrier is the lack of a reliable assessment 
for tumor LKB1 inactivation that can be used in clinical trials 
for patient selection and treatment evaluation. Current clinical 
LKB1 analysis includes evaluation of LKB1 mutations through 
sequencing 9 coding exons and flanking region of the LKB1 gene 
as well as IHC assay of LKB1 protein expression. However, LKB1 
functional inactivation could result from mutations across the 
entire LKB1 gene, epigenetic silencing, or posttranslational inac-
tivation (20, 22, 50), posing a great challenge for detection of 
LKB1 functional loss through direct genomic sequencing. Also, 
not all LKB1 mutations impair LKB1 functions. IHC assay was 
shown to be a means to detect LKB1 protein loss (51); however, 
the LKB1 antibodies used in the study were not highly specific. 
Recently, a 16-gene signature was reported to be capable of pre-
dicting tumor cells with LKB1 inactivation (35). Yet expression 
of those individual genes is not completely correlated with the 
tumor LKB1 status, and combined scoring of multiple genes for 
individual tumors requires complicated analysis.
Figure 5. LINC00473 shows predominantly nuclear localization with dis-
tinct nuclear structures. (A) Transcript levels of LINC00473 and U6 (a nuclear 
marker) in the nuclear (Nuc) and cytoplasmic (Cyt) fractions obtained from 
A549 cells were quantified by qRT-PCR assays. (B) LINC00473 transcripts 
were enriched in the nuclear compartment when compared with nuclear 
marker U6 and cytoplasmic marker tRNA by Northern blot analysis in three 
separate nuclear (N) and cytoplasmic (C) fractions obtained from A549 cells. 
(C) Nuclear localization of LINC00473 was detected by RNA-FISH in A549 
cells. LINC00473 RNA-FISH probe sets were labeled with Quasar 570 dyes 
(red), and nuclei were labeled with the DNA dye DAPI (blue). Scale bars:  
10 µm. See also Supplemental Figure 12.
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fore, approaches for targeting LINC00473 expression for block-
ing NSCLC should be further investigated.
We identified an upstream LKB1/CRTC/CREB signaling axis 
directly controlling LINC00473 transcription. LINC00473 expres-
sion is strongly tied with the LKB1 signaling in different cellular 
contexts, as we observed that upregulation of LINC00473 is tightly 
linked with LKB1 functional status in spite of many other gene 
mutations coexisting in cancer cells. Future detailed analysis of the 
LINC00473 promoter/enhancer is necessary to gain insights into 
the tight, specific regulation by the LKB1 pathway. LINC00473 is 
a nuclear lncRNA, and the distinct nuclear pattern of LINC00473 
is intriguing. Mechanistically, LINC00473 promotes the recruit-
ment of NONO to CRTCs and enhances transcriptional activation 
of CREB-mediated transcription. Our data thus identified a function 
for LINC00473 in assisting with the recruitment of critical factors 
to assemble active CRTC/CREB transcription complexes and pro-
mote transcription, elucidating a potential positive feedback mech-
anism for LINC00473 in regulating gene expression. These data are 
consistent with the finding that LINC00473 depletion reduced the 
expression of a set of genes that are induced by LKB1 loss, suggesting 
that LINC00473 likely mediates certain effects of the loss of LKB1 
Patients with high LINC00473–expressing lung cancers had 
shorter survival times, suggesting that LINC00473 likely confers 
lung cancer cells with aggressive behaviors. Interestingly, a sub-
stantial number of lncRNAs in the human genome seem to have 
arisen within the primate lineage based on sequence conserva-
tion (52), and LINC00473 belongs to this group. It is unclear 
whether LINC00473 may contribute to any unique features asso-
ciated with human cancers. Our functional data strongly indicate 
an essential role for LINC00473 in maintaining human NSCLC 
cell growth and survival. LINC00473 has low or undetectable 
expression in normal tissues; therefore, targeting LINC00473 
expression is an attractive approach for specifically blocking 
lung cancer without significantly affecting normal tissues. Cur-
rently, anticancer drugs mainly target DNA or proteins in tumor 
cells. Therapeutic development for RNA-based targeting is in its 
infancy, but various new approaches are being explored, such as 
antisense oligonucleotides and RNAi. Progress has been made 
to improve delivery and specificity. For example, first proof-of- 
principle RNAi therapeutics based on RNAi and lipid nanoparti-
cles (LNPs) has been tested in humans (53), supporting further 
development of RNA-targeting drugs in treating cancers. There-
Figure 6. LINC00473 is associated with NONO protein and stimulates CRTC-NONO interaction. (A) Coomassie blue staining of the LINC00473-associated 
proteins by RNA pull-down in A549 cells. (B) Specific association of LINC00473 RNA with NONO protein was validated through RNA pull-down followed by 
Western blot analysis. LINC00473 antisense and MEG RNA were used as controls. (C) Immunoprecipitation of endogenous NONO protein was validated via 
Western blotting (HC, heavy chain). (D) LINC00473 was significantly enriched in NONO immunoprecipitates relative to the IgG control by qRT-PCR assay. ASNS 
was used as a negative control (n = 3, ***P < 0.0001). (E) Depletion of LINC00473 caused reduced CRTC1-NONO interaction. A549 cells, after transduction 
with LINC00473 shRNA (shLINC00473-2 and -4) or the scramble shRNA lentiviruses (Ctl) for 72 hours, were cotransfected with Gal4-NONO, pSG5-luc (a firefly 
luciferase reporter containing Gal4-binding sites), pEF-RL (Renilla luciferase), as well as vector control or CRTC1. The luciferase activity was measured 24 hours 
after transfection (n = 3, *P < 0.05). (F) Overexpression of LINC00473 enhanced CRTC1-NONO interaction. HEK293T cells were transfected with Gal4-NONO, 
CRTC1, pSG5-luc, or pEF-RL in the presence of vector or LINC00473 construct. The luciferase activity was determined at 24 hours after transfection (n = 3,  
***P < 0.0001). (G) Relative expression levels of LKB1-regulated genes in shLINC00473- versus shCtl-expressing A549 cells and in LKB1 versus vector control 
A549 cells showed that LINC00473 depletion attenuated some common target gene expression induced by LKB1 loss. See also Supplemental Figure 13.
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retroviruses for 96 hours, and two biological 
replicates were set up. RNAs were subjected 
to human lncRNA expression microarray 
(V3.0) analyses (ArrayStar). The microarray 
data were deposited in NCBI Gene Expres-
sion Omnibus (GEO GSE73414). Genes with 
an absolute fold change of ≥2 and P value < 
0.05 were considered as significantly differ-
entially expressed.
NanoString nCounter gene expression 
analysis. NanoString gene expression 
assay analyses were performed according 
to the manufacturer’s protocols (Nano-
String Technologies) using our customized 
nCounter GX CodeSet. In brief, total RNA 
from cultured cells (100 ng) or RNA from 
FFPE tissues (150–200 ng) were hybrid-
ized with the specific capture probes and 
barcoded reporter probes at 65°C for 18 
hours and then loaded into the nCounter 
Pre-station for purification of the hybrid-
ized probes. Data collection was performed 
on the nCounter Digital Analyzer, which 
counted and tabulated the individual fluo-
rescent barcodes for target RNA molecules 
in each sample following the manufactur-
er’s instructions. The raw data were ana-
lyzed with nSolver Analysis Software for 
gene expression analysis. The heatmap was generated with the Heat-
map.2 R package (https://cran.r-project.org/web/packages/gplots/
index.html) using the normalized NanoString expression data.
RNA ISH. RNA ISH was performed on FFPE xenograft tumors 
and tissue microarrays (TMAs) using an RNAscope 2.0 HD Reagent 
Kit (BROWN 310033 or RED 310034, Advanced Cell Diagnostics 
[ACD]). Briefly, tissue sections were deparaffinized with xylene and 
100% ethanol, and then incubated with pretreat 1 solution for 10 
minutes, pretreat 2 for 15 minutes, and pretreat 3 for 30 minutes 
(Pretreatment kit 310020, ACD). The slides were then hybridized 
with a custom probe, Hs-LINC00473 tv1 (targeting 781-1755 of 
NR_026860.1), in the HybEZ oven (ACD) at 40°C for 2 hours. The 
Hs-PPIB probe for human housekeeping gene PPIB was used as a 
control to ensure RNA quality. After hybridizations, slides were sub-
jected to signal amplification using an HD 2.0 Detection Kit, and 
hybridization signal was detected using a mixture of solutions A and 
B (1:60). After counterstaining with hematoxylin, slides were dried 
in a 60°C dry oven for 15 minutes and mounted with EcoMount (Bio-
Care Medical, EM897L). The stained sections were scanned and 
digitized with Aperio Imagescope (Leica).
RNA-FISH. RNA-FISH was performed using LINC00473 Stel-
laris FISH probes labeled with Quasar 570 (LGC Biosearch Technolo-
gies) following the manufacturer’s protocol. Imaging was performed 
immediately using a Leica DM6000B fluorescence microscope.
Proteomic analysis of the LINC00473-associated protein complex. 
lncRNA was first transcribed in vitro using the MEGAscript T7 Tran-
scription Kit (AM1333, Life Technologies) according to the manu-
facturer’s instructions. Identification of lncRNA-interacting protein 
complexes was performed as previously described, with modifica-
tumor suppression. It should be noted that LINC00473 appeared 
to have a negative feedback regulation in normal cells after cAMP 
stimulation, as LINC00473 RNAi caused moderate transcriptional 
upregulation of cAMP signaling–responsive genes in response to an 
EP2 agonist (43). The molecular action of LINC00473 in regulating 
cAMP/CREB signaling should be further investigated and compared 
between normal cells with low or undetectable basal LINC00473 
expression and cancer cells with sustained high LINC00473 expres-
sion. Finally, LINC00473 most likely has other mechanisms that 
contribute to its regulatory functions. Elucidation of the endogenous 
chromatin-associated LINC00473 binding sites as well as down-
stream target genes will provide mechanistic insights into the roles 
of this lncRNA in lung tumorigenesis.
In summary, we identified a nuclear lncRNA LINC00473 
whose expression has potential utility in classifying LKB1 func-
tional status in human NSCLC and is associated with poor patient 
survival. Sustained LINC00473 expression is essential for main-
taining NSCLC cell growth and survival, supporting the notion 
that targeting LINC00473 is an effective strategy to specifi-
cally block NSCLC growth. Finally, we identified a function for 
LINC00473 in regulating gene expression. Collectively, this study 
reveals mechanistic insights into the roles of LINC00473 in lung 
cancers and supports the use of LINC00473 as a biomarker and a 
therapeutic target for LKB1-inactivated lung cancers.
Methods
Additional experimental details are included in Supplemental Methods.
lncRNA microarray analysis. Total RNAs were extracted from A549 
cells after the transduction of WT LKB1, LKB1 K78I mutant, or control 
Figure 7. A model for the molecular basis of LINC00473 induction and the role of sustained 
LINC00473 expression as a potential biomarker and prognostic marker, therapeutic target, and gene 
regulator for LKB1-inactivated NSCLC.
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tions (54, 55). Briefly, RNAs were covalently linked to adipic acid 
dihydrazide agarose beads by periodate oxidation of the RNA 3′-OH 
terminus. The beads bound with RNAs were incubated with nuclear 
extracts of A549 cells to pull down the lncRNA-interacting proteins. 
After extensive washing, beads were boiled with a loading buffer to 
elute the lncRNA-interacting proteins, which were further separated 
by SDS-PAGE and subjected to mass spectrometric analysis.
Mouse xenograft studies. Luciferase-expressing A549 cells or 
H157 cells infected with control shRNA or shLINC00473 lentivi-
ruses were subcutaneously injected to NOD/SCID mice (The Jack-
son Laboratory). Tumors were measured, and bioluminescence 
imaging was performed as previously described (56).
Analysis of RNA sequencing and clinical data. RNA sequencing 
data from the LUAD dataset of the TCGA sequencing project and 
the accompanying clinical data (40) were used for analysis. Nor-
malized read counts (RSEM; http://deweylab.github.io/RSEM/) 
for each LUAD sample aligned to LINC00473 were obtained and 
used for the survival curve analysis. LUAD samples with ≥90th per-
centile of LINC00473 expression and those with <90th percentile 
were considered as high and low groups, respectively. The overall 
survival was analyzed by Kaplan-Meier curves and log-rank test for 
all LUAD patients. P values less than 0.05 were considered statis-
tically significant.
Statistics. Data from qRT-PCR, reporter assay, cell proliferation, 
apoptosis, and in vivo xenograft experiments were analyzed using 
2-tailed Student’s t test. Results are expressed as mean and ± SD, 
and a P value less than 0.05 was considered statistically significant. 
The biological replicates for each experiment are indicated in the 
figure legends.
Study approval. All mouse experiments were performed in accor-
dance with a protocol approved by the IACUC of the University of 
Florida. This study has qualified as exempt review for human subjects 
research by the University of Florida Institutional Review Board.
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